Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2022

View Archived Issues

Researchers present new murine model of aeroallergen-induced EoE

Clarity Pharmaceuticals describes new radiopharmaceuticals

Abm Therapeutics identifies new AXL/PAK1/c-KIT/RET/MAP4K1 inhibitors

New prodrugs of PIN1 inhibitors discovered at the University of California

New mucolipin-1 agonists divulged by Casma Therapeutics

Cornell University patents PROTACs targeting BET domain proteins

Targeting alpha2-Na+/K+ ATPase improves tau pathology in vivo

Phenanthroline derivative with antitumor activity in liver cancer models

Engineered retinal cells stare daggers at peritoneal tumors

TRIM14 is a potential therapeutic target for treating inflammation-driven diseases

Biomind reports in vivo findings with DMT combination drug BMND-07

Inhibiting DsbA inactivates resistance enzymes, sensitizing AMR bacteria to existing antibiotics

Procoagulant nanoparticles as platelet surrogates for management of bleeding

ATH-1017 positively modulates HGF/MET axis and shows procognitive effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.